Our Steps to Translating Visions into Realities

Global Leader in Genome-based Personalized Medicine

Leading Innovative Genomic Biotechnology

Our Work Does Not End Genomics, Promising Impact for Our Communities

Theragen is a comprehensive pharmaceutical and biotechnology group
Providing outstanding genetic analysis services and progressing personalized new drug development
Bio Institute DivisionRead More Pharmaceutical DivisionRead More

Holding of core competence for precision medicine era The paradigm of future medicine in the fourth industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex receives more attention because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision medicine.”

The world’s highest level of genome analysis technology Theragen Etex has made excellent achievements using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual genome analysis service in Asia. The company is now poised to benefit from the new growth engine.

International GMP certified facilities, stable manufacturing and supply of medicines Pharmaceutical Division increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.

Carcinogenic gene analysis and development of novel anticancer drug With the cooperation of the world’s best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under clinical trial in Korea and the US.

About Us Group companies make efforts to achieve a healthier and happier tomorrow.

News

2018
29Jun Genome Care to provide 2 infertility aid services

Genome Care, a subsidiary of Theragen Etex, said that it plans to launch two new inspection services that can increase the implantation rate of artificial insemination in infertile women.   The two services are end...

21Jun Wins patent for immunotherapy research using big data

Theragen Etex has registered a patent regarding the use of big data technology in immunotherapy research.   This is the first time that a domestic biotech company obtained a patent in the field of providing biometr...

07Jun Medpacto to unveil P1 clinical trial on immunotherapy

Medpacto presents its phase 1 clinical trial results on Vactosertib, an immunotherapy agent, during the upcoming 2018 American Society of Clinical Oncology next month.   Vactosertib is a drug candidate that selecti...

31May Dr. Kim Sung-jin Wins JCA International Award

Dr. Kim Sung-jin Wins JCA International Award Terazen's ESI Biotechnology Research Institute (Terazen) said that Dr. Kim Sung-jin (Vice President of Technology) won the JCA International Award at the Japan Can...

31May Theragen Genomecare to export Genomom to UAE and Middle East

Theragen Genomecare, which is a subsidiary of Theragen Etex, announced to export NIPT (Non-Invasive Prenatal Test) technology in UAE and Middle East. Theragen Genomecare is the first NIPT service company in Kroea to h...

09Apr Theragen Etex Bio Institute launches gene big data services

Theragen Etex Bio Institute, which is a leading company of genetic-based precision medicine, has started gene diagnosis service using Nove-Seq platform.   Nova-Seq is ilumina's new sequencing platform that can ...

CONTACT US

Bio Institute Division: 1522-2375
Pharmaceutical Division: 02-3463-7111
Bio Institute Division: AICT Bldg., A, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16229
Pharmaceutical Division: Daegwan Bldg., 190 Gangnam-daero, Seocho-gu, Seoul
Bio Institute Division: 031-888-9440
Pharmaceutical Division: 02-3463-8111
Bio Institute Division: bio@theragenetex.com
Pharmaceutical Division: etex@etexpharm.com